| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 5.61 | 15.81 | 13.13 | 6.77 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | 1.11 | 1.36 |
| 6.07 | 16.57 | 15.23 | 8.89 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.77 | 2.41 | 2.86 | 1.66 |
| ST’ Debt | 4.00 | 6.79 | 0.99 | — |
| Other | — | — | — | — |
| 7.29 | 12.68 | 7.74 | 6.60 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (13.83) | — | — |
—
|
| ’25 | — | (12.71) | — | (27.88) |
(27.88)
|
| ’24 | — | (8.49) | — | (21.96) |
(21.96)
|
| ’23 | — | (8.28) | — | (17.24) |
(17.24)
|
| ’22 | — | (20.34) | — | (34.32) |
(34.32)
|
| ’21 | — | (13.55) | — | (32.39) |
(32.39)
|
| ’20 | (4.69) | (2.76) | — | (21.60) |
(21.60)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (14.04) | — | — |
—
|
| ’25 | — | (12.73) | — | (28.09) |
(28.09)
|
| ’24 | — | (8.51) | — | (22.04) |
(22.04)
|
| ’23 | — | (8.48) | — | (17.43) |
(17.43)
|
| ’22 | — | (21.53) | — | (36.08) |
(36.08)
|
| ’21 | — | (13.94) | — | (35.04) |
(35.04)
|
| ’20 | (5.16) | (2.90) | — | (22.38) |
(22.38)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.35) | (0.35) | — | — |
—
|
| ’25 | (0.70) | (0.78) | (0.37) | (0.41) |
(2.09)
|
| ’24 | (1.37) | (1.25) | (1.22) | (1.13) |
(4.91)
|
| ’23 | (8.41) | (3.90) | (3.40) | (3.97) |
(16.93)
|
| ’22 | (18.92) | (18.32) | (14.41) | (9.61) |
(60.96)
|
| ’21 | (14.11) | (16.82) | (15.92) | (21.32) |
(67.87)
|
| ’20 | (0.59) | (759.76) | (10.51) | (12.31) |
(122.22)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.50 | 3.57 | 2.37 | 2.30 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 207.00 | 38.70 | 9.20 | 4.63 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 69 | 79 | 61 | 62 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (39.43) | (23.80) | (28.98) | (34.16) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (39.56) | (23.86) | (29.02) | (34.17) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.72 | 1.82 | 1.62 | 1.46 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (60.96) | (16.99) | (4.91) | (2.09) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (52.99) | (12.27) | (3.71) | (1.70) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.73) | (0.14) | (0.01) | (0.01) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (55.72) | (12.41) | (3.73) | (1.72) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.00 | (1.49) | 1.30 | 0.67 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.65 | 1.40 | 5.91 | 16.35 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (34.32) | (17.24) | (21.96) | (27.88) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.77) | (0.20) | (0.08) | (0.21) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (36.08) | (17.43) | (22.04) | (28.09) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.64 | (1.22) | 3.89 | 7.49 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 11.60 | 10.38 | 7.42 | 0.99 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.51) | 4.77 | (8.39) | (12.14) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.83 | (2.10) | 7.68 | 10.97 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (112.69%) | (115.45%) | (142.99%) | (143.79%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (562.36%) | (533.88%) | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (189.32%) | (1,278.60%) | (1,038.73%) | (366.29%) | — | — | — |
ROE
|
PolyPid Ltd. (PYPD), an Israeli biotech pioneer in polymer-based drug delivery implants like PLEXZ for surgical pain and ONYX for infection prevention, embodies the rollercoaster of pre-revenue investing. Over the past decade, it’s battled heavy R&D cash burn, aggressive share dilution (up 123%), and a stock plunge of 98% from pandemic highs, mirroring many speculative biotechs. Cumulative losses top $200 million, but recent narrowing deficits—EBT improved 22% to -$29 million in 2024—and a healthier balance sheet with positive equity and slashed debt offer glimmers of stability.
Analysts forecast a game-changer: $23.4 million in revenue for 2025-2026 from PLEXZ’s U.S. launch, slashing losses by 69% initially and paving a path to breakeven, with price targets implying 100-220% upside from current levels. Insider silence adds caution, but improving metrics and a $12 million net cash runway fuel optimism amid a massive surgical market.
Yet risks loom large—execution delays, trial failures (90% Phase 3 odds), geopolitical tensions, and dilution history could derail progress. Like past winners such as Pacira, PolyPid teeters at an inflection point: transformative gains for patient investors, or more pain? Dive into the full analysis for the numbers and parallels that could make or break this high-stakes bet.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.